Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian T Tsuji

Showing results (11-20 of 103) with videos related to

Pageof 11
Sort By:
Antimicrobial Agents and Chemotherapy|December 13, 2006
Evaluation of accessory gene regulator (agr) group and function in the proclivity towards vancomycin intermediate resistance in Staphylococcus aureusBrian T Tsuji, Michael J Rybak, Kerry L Lau, et al.
Antibiotics (Basel, Switzerland)|April 25, 2019
Shifting Gears: The Future of Polymyxin AntibioticsJustin R Lenhard, Zackery P Bulman, Brian T Tsuji, et al.
Journal of Chemotherapy (Florence, Italy)|February 26, 2013
Activity of AFN-1252, a novel FabI inhibitor, against Staphylococcus aureus in an in vitro pharmacodynamic model simulating human pharmacokineticsBrian T Tsuji, Yoriko Harigaya, Alan J Lesse, et al.
BMC Infectious Diseases|October 27, 2011
Characterization of heterogeneous vancomycin-intermediate resistance, MIC and accessory gene regulator (agr) dysfunction among clinical bloodstream isolates of staphyloccocus aureusYoriko Harigaya, Dung Ngo, Alan J Lesse, et al.
Diagnostic Microbiology and Infectious Disease|April 7, 2009
Loss of vancomycin bactericidal activity against accessory gene regulator (agr) dysfunctional Staphylococcus aureus under conditions of high bacterial densityBrian T Tsuji, Yoriko Harigaya, Alan J Lesse, et al.
International Journal of Antimicrobial Agents|May 21, 2013
Pharmacokinetic/pharmacodynamic evaluation of the efficacy and safety of daptomycin against Staphylococcus aureusRachel L Soon, Stuart J Turner, Alan Forrest, et al.
Diagnostic Microbiology and Infectious Disease|February 16, 2007
Community- and health care-associated methicillin-resistant Staphylococcus aureus: a comparison of molecular epidemiology and antimicrobial activities of various agentsBrian T Tsuji, Michael J Rybak, Chrissy M Cheung, et al.
The Journal of Antimicrobial Chemotherapy|April 17, 2007
Correlation of vancomycin and daptomycin susceptibility in Staphylococcus aureus in reference to accessory gene regulator (agr) polymorphism and functionWarren E Rose, Michael J Rybak, Brian T Tsuji, et al.
Antimicrobial Agents and Chemotherapy|February 21, 2008
Attenuated vancomycin bactericidal activity against Staphylococcus aureus hemB mutants expressing the small-colony-variant phenotypeBrian T Tsuji, Christof von Eiff, Pamela A Kelchlin, et al.
The Journal of Antimicrobial Chemotherapy|April 11, 2008
In vitro pharmacodynamics of novel rifamycin ABI-0043 against Staphylococcus aureusBrian T Tsuji, Jenny C Yang, Alan Forrest, et al.
Pageof 11

Showing results (11-20 of 103) with videos related to

Sort By:
Pageof 11
Antimicrobial Agents and Chemotherapy|December 13, 2006
Evaluation of accessory gene regulator (agr) group and function in the proclivity towards vancomycin intermediate resistance in Staphylococcus aureusBrian T Tsuji, Michael J Rybak, Kerry L Lau, et al.
Antibiotics (Basel, Switzerland)|April 25, 2019
Shifting Gears: The Future of Polymyxin AntibioticsJustin R Lenhard, Zackery P Bulman, Brian T Tsuji, et al.
Journal of Chemotherapy (Florence, Italy)|February 26, 2013
Activity of AFN-1252, a novel FabI inhibitor, against Staphylococcus aureus in an in vitro pharmacodynamic model simulating human pharmacokineticsBrian T Tsuji, Yoriko Harigaya, Alan J Lesse, et al.
BMC Infectious Diseases|October 27, 2011
Characterization of heterogeneous vancomycin-intermediate resistance, MIC and accessory gene regulator (agr) dysfunction among clinical bloodstream isolates of staphyloccocus aureusYoriko Harigaya, Dung Ngo, Alan J Lesse, et al.
Diagnostic Microbiology and Infectious Disease|April 7, 2009
Loss of vancomycin bactericidal activity against accessory gene regulator (agr) dysfunctional Staphylococcus aureus under conditions of high bacterial densityBrian T Tsuji, Yoriko Harigaya, Alan J Lesse, et al.
International Journal of Antimicrobial Agents|May 21, 2013
Pharmacokinetic/pharmacodynamic evaluation of the efficacy and safety of daptomycin against Staphylococcus aureusRachel L Soon, Stuart J Turner, Alan Forrest, et al.
Diagnostic Microbiology and Infectious Disease|February 16, 2007
Community- and health care-associated methicillin-resistant Staphylococcus aureus: a comparison of molecular epidemiology and antimicrobial activities of various agentsBrian T Tsuji, Michael J Rybak, Chrissy M Cheung, et al.
The Journal of Antimicrobial Chemotherapy|April 17, 2007
Correlation of vancomycin and daptomycin susceptibility in Staphylococcus aureus in reference to accessory gene regulator (agr) polymorphism and functionWarren E Rose, Michael J Rybak, Brian T Tsuji, et al.
Antimicrobial Agents and Chemotherapy|February 21, 2008
Attenuated vancomycin bactericidal activity against Staphylococcus aureus hemB mutants expressing the small-colony-variant phenotypeBrian T Tsuji, Christof von Eiff, Pamela A Kelchlin, et al.
The Journal of Antimicrobial Chemotherapy|April 11, 2008
In vitro pharmacodynamics of novel rifamycin ABI-0043 against Staphylococcus aureusBrian T Tsuji, Jenny C Yang, Alan Forrest, et al.
Pageof 11